Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
27.74 (1y: +140%)
Market Cap 557.88 M P/E(ttm) 9247.00
Enterprise Value 579.64 M P/B 21.30
LGND- NAS (USA)
Ligand Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$27.74
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 0.272
LGND's Cash to Debt is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. LGND: 0.272 )
LGND' s 10-Year Cash to Debt Range
Min: 0.18   Max: 43.81
Current: 0.27
0.18
43.81
Equity to Asset -0.4
LGND's Equity to Asset is ranked lower than
97% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. LGND: -0.4 )
LGND' s 10-Year Equity to Asset Range
Min: -0.82   Max: 0.27
Current: -0.4
-0.82
0.27
Interest Coverage 0.2
LGND's Interest Coverage is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. LGND: 0.2 )
LGND' s 10-Year Interest Coverage Range
Min: 0   Max: No Debt
Current: 0.2
F-Score: 7
Z-Score: -4.85
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 1.80
LGND's Operating margin (%) is ranked lower than
83% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. LGND: 1.80 )
LGND' s 10-Year Operating margin (%) Range
Min: -466.7   Max: 1.8
Current: 1.8
-466.7
1.8
Net-margin (%) -1.7
LGND's Net-margin (%) is ranked lower than
77% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. LGND: -1.7 )
LGND' s 10-Year Net-margin (%) Range
Min: -359.2   Max: 2184.6
Current: -1.7
-359.2
2184.6
ROE (%) -2
LGND's ROE (%) is ranked lower than
75% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. LGND: -2 )
LGND' s 10-Year ROE (%) Range
Min: -116.1   Max: 967.5
Current: -2
-116.1
967.5
ROA (%) -0.5
LGND's ROA (%) is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. LGND: -0.5 )
LGND' s 10-Year ROA (%) Range
Min: -63.8   Max: 162.6
Current: -0.5
-63.8
162.6
Revenue Growth (%) -6.4
LGND's Revenue Growth (%) is ranked higher than
78% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. LGND: -6.4 )
LGND' s 10-Year Revenue Growth (%) Range
Min: -50.6   Max: 23.3
Current: -6.4
-50.6
23.3
EPS Growth (%) -29.3
LGND's EPS Growth (%) is ranked lower than
78% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. LGND: -29.3 )
LGND' s 10-Year EPS Growth (%) Range
Min: -52.4   Max: 20.4
Current: -29.3
-52.4
20.4
ยป LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q1 2012

LGND Guru Trades in Q1 2012

Jim Simons 14,994 sh (New)
» More
Q2 2012

LGND Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q4 2012

LGND Guru Trades in Q4 2012

Jim Simons 33,888 sh (New)
» More
Q1 2013

LGND Guru Trades in Q1 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LGND

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2011-12-31 Sold Out 0.46%$10.59 - $15.73 $ 27.74117%0
George Soros 2011-09-30 Sold Out 0.0017%$10.89 - $15.95 $ 27.74110%0
Daniel Loeb 2011-06-30 Add 110.73%0.16%$9.56 - $12.02 $ 27.74163%705016
George Soros 2011-06-30 New Buy$9.56 - $12.02 $ 27.74163%10000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 9247.00
LGND's P/E(ttm) is ranked lower than
56% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.76 vs. LGND: 9247.00 )
LGND' s 10-Year P/E(ttm) Range
Min: 0.95   Max: 9336.67
Current: 9247
0.95
9336.67
P/B 21.30
LGND's P/B is ranked lower than
84% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. LGND: 21.30 )
LGND' s 10-Year P/B Range
Min: 3.72   Max: 182
Current: 21.3
3.72
182
P/S 14.81
LGND's P/S is ranked lower than
89% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. LGND: 14.81 )
LGND' s 10-Year P/S Range
Min: 2.23   Max: 41.62
Current: 14.81
2.23
41.62
PFCF 277.40
LGND's PFCF is ranked lower than
70% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. LGND: 277.40 )
LGND' s 10-Year PFCF Range
Min: 52.65   Max: 558.96
Current: 277.4
52.65
558.96
EV-to-EBIT 111.1
LGND's EV-to-EBIT is ranked lower than
63% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. LGND: 111.1 )
LGND' s 10-Year EV-to-EBIT Range
Min: 83.5   Max: 821.4
Current: 111.1
83.5
821.4
Shiller P/E 12.6
LGND's Shiller P/E is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.12 vs. LGND: 12.6 )
LGND' s 10-Year Shiller P/E Range
Min: 2.87   Max: 274
Current: 12.6
2.87
274

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 132.1
LGND's Price/Net Current Asset Value is ranked higher than
97% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. LGND: 132.1 )
LGND' s 10-Year Price/Net Current Asset Value Range
Min: 24.1   Max: 821.3
Current: 132.1
24.1
821.3
Price/Median PS Value 1.8
LGND's Price/Median PS Value is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. LGND: 1.8 )
LGND' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 4.4
Current: 1.8
0.5
4.4
Earnings Yield (Greenblatt) 0.90
LGND's Earnings Yield (Greenblatt) is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. LGND: 0.90 )
LGND' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.2
Current: 0.9
0.1
1.2
Forward Rate of Return (Yacktman) -3.64
LGND's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.82 vs. LGND: -3.64 )
LGND' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -32.1   Max: -4.4
Current: -3.64
-32.1
-4.4

Business Description

Ligand Pharmaceuticals is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies, more convenient to administer and are cost effective. Ligand currently receives royalty revenues from King Pharmaceuticals, or King, and GSK. In February 2007, the company completed the sale of its AVINZA product line to King. As a result of the sale, it received the right to future royalties on the net sales of AVINZA through 2017. Lasofoxifene is a product candidate that resulted from Ligand's collaboration with Pfizer. Pfizer submitted an NDA and an MAA for FABLYN for osteoporosis treatment in December 2007 and January 2008, respectively. The company is developing small molecule agonists for the EPO receptor. EPO stimulates the differentiation of bone marrow stem cells to form red blood cells. Various recombinant human EPO derivatives are marketed for the treatment of anemia due to renal failure or cancer chemotherapy. Ligand is developing SGRMs for inflammation, cancer indications and other therapeutic applications. The company has a library of compounds that it is optimizing with the goal to identify one or more compounds to enter human trials. Ligand's studies of these compounds are in the research stage. The company's drug discovery approach is further supported by its proprietary combinatorial chemistry encoding technology, Encoded Combinatorial Libraries on Polymeric Support, or ECLiPS, the company's proprietary collection of chemical compounds, assay technology, production automation, information systems and quality assurance programs. Ligand currently has no manufacturing facilities and, accordingly, relies on third parties, including its collaborative partners, for clinical production of any products or compounds.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:LGDN.Germany
ยป More Articles for LGND

Headlines

Articles On GuruFocus.com
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial